Here's why the OncoSil Medical (ASX:OSL) share price has jumped 10% today

The OncoSil Medical Ltd (ASX: OSL) share price jumped 10% after receiving Swiss regulatory approval. We take a closer look.

| More on:
jump in asx share price represented by man leaping up from one wooden pillar to the next

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The OncoSil Medical Ltd (ASX: OSL) share price jumped 10% on Thursday after the company received regulatory clearance to market and sell its products in Switzerland.

About OncoSil

OncoSil is focused on localised treatments for patients with pancreatic and liver cancer. Its lead product is a first class medical device with target radioactive isotope, which is implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound. This treatment, known as brachytherapy, is intended to deliver more concentrated and localised radiation. OncoSil is currently approved in the EU, UK, Singapore, Malaysia and New Zealand.

The company has a market capitalisation of $125 million. As a small cap, the OncoSil share price has seen heightened levels of volatility, especially amid COVID-19. Despite the company's medical advancements and regulatory approvals, its share price has not made a new high since early 2016.

OncoSil receives Swiss regulatory approval

Switzerland is the latest country to provide clearance to market and sell the OncoSil device. The company reports that Switzerland is an attractive market for OncoSil and is highly receptive to innovative technologies. Healthcare spending per capita is high in comparison to other European markets, and private medical insurance is compulsory for all persons in Switzerland.

This follows on from the European Breakthrough Device designation the company received in April 2020, which covers the UK and EU.

First commercial sale

On 22 October, the company achieved its first revenues after its first commercially treated patient was implanted with the OncoSil device in New Zealand. The company described it as a "very significant achievement for OncoSil and marks the company's transition towards being a revenue-generating medical device company."

To facilitate its first revenues in Europe by the end of the year, the company has onboarded multiple hospitals throughout Europe and established a central radio-pharmacy in the UK, which will dispense the OncoSil device in up to 15 hospitals in the greater London area. The company cites that another severe lockdown across Europe as a result of COVID remains the greatest unknown factor for its planned launch timeline.

The pandemic has slowed launch preparations including site training and certification work. Despite these interruptions, the company aims to continue preparations to launch in Europe and remain on track for first revenues in Q4 2020.

Today's news has seen the OncoSil share price push higher to 16.5 cents this afternoon.

Motley Fool contributor Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Contented looking man leans back in his chair at his desk and smiles.
Share Market News

5 things to watch on the ASX 200 on Thursday

Will the market continue to rise? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Broker Notes

The smartest Australian stocks to buy with $250 right now

$250 to invest? Check out these stocks that brokers rate as buys.

Read more »

Rising gold share price represented by a green arrow on piles of gold block.
Share Gainers

2 ASX All Ords stocks that would already have more than doubled your money this year

These ASX All Ords stocks have gained 126% and 145% year to date. But how?

Read more »

A woman wearing dark clothing and sporting a few tattoos and piercings holds a phone and a takeaway coffee cup as she strolls under the Sydney Harbour Bridge which looms in the background.
Broker Notes

1 magnificent Aussie stock down 23% to buy and hold forever

Let's see why this could be a top share to buy while it is down.

Read more »

Ten smiling business people wave to the camera after receiving some winning company news.
Share Gainers

Here are the top 10 ASX 200 shares today

It was an historic day for the ASX, with the market setting a new record.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Broker Notes

Bell Potter says this ASX 200 stock can rise 100%+

Let's see which stock the broker is tipping as a buy to clients.

Read more »

Man sitting in a plane looking through a window and working on a laptop.
Broker Notes

Macquarie tips 28% upside for this ASX All Ords tech stock

Let's see what the broker is saying about this growth stock.

Read more »